Advertising and Promotional Requirements for Drugs and Medical Devices 2014
conferences > Health conferences > Advertising and Promotional Requirements for Drugs and Medical Devices
August 7 - 8, 2014
San Diego CA , USA
This Seminar is Pre- approved by RAPS as eligible for up to 12 credits towards a participant's RAC recertification upon full completion.
Overview:
The changing game for drug and device marketing, however, is governed by antiquated and inadequate rules created for traditional print and broadcast advertising by the Food and Drug Administration ("FDA"). How the FDA will deal with such advanced communication technology that can go "viral" and just as quickly disappear is the question that the industry is eager to have answered.
The FDA regulates the promotion of prescription drugs, biologics, medical devices and biotechnology products to ensure that the information is not false or misleading. The FDA has for decades regulated traditional advertising for decades, published various guidance documents for industry and issued many violation letters. If the FDA determines that drug or medical device promotional material is false or misleading or lacking in fair balance as between benefits and risks, companies could be forced to implement costly corrective actions, such as remedial advertising, suffer damage to their reputations and incur monetary fines. Already, the government has collected billions of dollars in fines, forfeitures and disgorgements from drug companies for the alleged marketing of a product for unapproved, or "off-label," uses.
ABOUT SPEAKER –
David R. Dills
Regulatory Affairs & Compliance Consultant,
Price: $1,295.00
Discount:
Register now and save $200. (Early Bird)
Until June 15, Early Bird Price: $1,295.00
from June 16 to August 05, Regular Price: $1,495.00
Location2: Chicago Date: September 4th & 5th 2014 Time: 9 AM to 6 PM PDT
Overview:
The changing game for drug and device marketing, however, is governed by antiquated and inadequate rules created for traditional print and broadcast advertising by the Food and Drug Administration ("FDA"). How the FDA will deal with such advanced communication technology that can go "viral" and just as quickly disappear is the question that the industry is eager to have answered.
The FDA regulates the promotion of prescription drugs, biologics, medical devices and biotechnology products to ensure that the information is not false or misleading. The FDA has for decades regulated traditional advertising for decades, published various guidance documents for industry and issued many violation letters. If the FDA determines that drug or medical device promotional material is false or misleading or lacking in fair balance as between benefits and risks, companies could be forced to implement costly corrective actions, such as remedial advertising, suffer damage to their reputations and incur monetary fines. Already, the government has collected billions of dollars in fines, forfeitures and disgorgements from drug companies for the alleged marketing of a product for unapproved, or "off-label," uses.
ABOUT SPEAKER –
David R. Dills
Regulatory Affairs & Compliance Consultant,
Price: $1,295.00
Discount:
Register now and save $200. (Early Bird)
Until June 15, Early Bird Price: $1,295.00
from June 16 to August 05, Regular Price: $1,495.00
Location2: Chicago Date: September 4th & 5th 2014 Time: 9 AM to 6 PM PDT
Organizer
800-447-9407Related events
Advertising and Promotional Requirements for Drugs and Medical Devices August 7 - 8, 2014
